



XXI  
**INCLL**<sup>o</sup>  
International Workshop on CLL

**ABSTRACT GUIDELINES**

**KRAKÓW 2025**

12-15 September 2025 • [iwCLL2025.org](http://iwCLL2025.org)

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) seeks original abstracts that address **scientific questions**, demonstrate **new research/developments**, or contain **original scientific results** related to the treatment of patients with chronic lymphocytic leukemia (CLL).



XXI  
**INCLLO**

International Workshop on CLL

## Table of Contents

<b>ELIGIBILITY &amp; ABSTRACT TYPES</b>	<b>3</b>
• Abstract Eligibility	3
• Abstract Types Accepted	3
• Abstract Review & Selection	4
<b>HOW TO SUBMIT AN ABSTRACT</b>	<b>5</b>
• Author Information	6
• Abstract Information	7
• Additional Questions	
- Poster-Only Considerations (not required)	9
• Additional Questions	
- Encore and TiP Abstract Types (required)	10
• Attestation & Electronic Signature	11
• Submission	12
• Revisions	13
<b>PUBLICATIONS</b>	<b>13</b>
<b>WITHDRAWAL</b>	<b>14</b>
<b>COMMON FAQs</b>	<b>16</b>

# ELIGIBILITY & ABSTRACT TYPES

## ABSTRACT ELIGIBILITY

Abstracts are eligible to be accepted as the following:

	ORAL PRESENTATION	ORAL POSTER PRESENTATION	YIM ORAL PRESENTATION	YIM ORAL POSTER PRESENTATION	POSTER
Complimentary registration – Main Meeting	●	●			
Complimentary registration – YIM			●	●	
Presentation time	<b>10 min</b> (7 min presentation, 3 min Q&A)	<b>5 min</b> (3 min presentation, 2 min Q&A)	<b>10 min</b> (7 min presentation, 3 min Q&A)	<b>5 min</b> (3 min presentation, 2 min Q&A)	<b>N/A;</b> Poster displayed in live gallery during Main Meeting and on the Conference app's online Poster Gallery
Displayed as Poster		●	●	●	●
Publication	●	●	●	●	●

- The abstract must represent original work. Previously published work is discouraged, except for **Encore Abstracts**. (see below)
- Case reports and hypothesis-only submissions are discouraged.
- For all abstracts accepted as an **ORAL PRESENTATION, ORAL POSTER PRESENTATION, YIM ORAL PRESENTATION, or YIM ORAL POSTER PRESENTATION**, the presenting author must attend the XXI iwCLL meeting in Krakow, Poland. There is an option to select Poster-Only Acceptance during the submission process for those not wishing to be considered for presentation of any kind ([see page 9](#))
- iwCLL reserves the right to reject abstracts that fail to meet guidelines

## Abstract Types Accepted

### General

Clinical- and laboratory-based research on CLL, SLL, and B-cell lymphoproliferative disorders.

### Encore\*

Updated data from a previously presented abstract. Authors must disclose prior presentation details for identification and comparison purposes.

### Trials in Progress (TiP)

All phases of clinical research will be considered for a TiP submission. Submissions must include trial registration number and registry details.

### Late-Breaking General\*\*

General Abstract Types accepted during the late-breaking submission window of 05 July 2025 to 05 August 2025.

\*Note: Encores will not be considered if published or presented prior to 06 March 2025.

\*\*Note: These abstracts will only be accepted as posters.

## ABSTRACT REVIEW & SELECTION

Abstracts are peer-reviewed and scored based on:

Scientific  
quality

Innovation &  
impact

Relevance to  
iwCLL themes

Compliance  
with  
submission  
guidelines

Authors will receive acceptance or rejection notices by 01 July 2025.



### ABSTRACT KEY DATES

- 14 MAR 2025** YIM & iwCLL Call for Abstracts
- 30 MAY 2025** YIM & iwCLL Abstract Submission Deadline
- 01 JUL 2025** YIM & iwCLL Abstract Notifications
- 05 JUL 2025** General Abstract Late-Breakers Open
- 01 AUG 2025** Abstract Withdrawal Deadline
- 05 AUG 2025** General Abstract Late-Breakers Closed
- 08 AUG 2025** Abstract Titles Released
- 25 AUG 2025** Late-Breakers Notifications (rolling basis)

Submissions are editable until the **30 May 2025** submission deadline. Please refer to the list of deadlines above.

# HOW TO SUBMIT AN ABSTRACT

Below are the steps involved in submitting an abstract:

1. **Create an account**
2. **Complete Submission Task List:**
  - a. Author information
  - b. Abstract information
  - c. Additional questions related to submission type
  - d. Attestation & electronic signature
3. **Save and submit**

Submitters will be able to save a draft and return to complete the submission. Completed submissions will also be editable before the 30 May 2025 deadline date when you log back into the abstract submission system.

**NEW POLICY:** No figures, tables, or uploaded files are allowed in the abstract submissions

- Figures/tables may be included in presentations and posters but not in abstract submissions
- Accepted abstracts will be published in a peer-reviewed journal without tables or figures

**1. CREATE AN ACCOUNT:** Before beginning your abstract submission, you will be asked to create an account. You will also be required to create an access key that you will use to access your submission information in the future.

**2. COMPLETE SUBMISSION TASK LIST:** Below are the tasks you are responsible for completing prior to submitting an abstract.

GENERAL	ENCORE	TRIALS IN PROGRESS
<p><b>XXI Test Abstract</b> Abstract ID: 2082242 Abstract Type: General Abstract Category: Laboratory-based research Abstract Status: Active</p> <p>New abstract was successfully added.</p> <ol style="list-style-type: none"><li>1. <b>Author Information</b> Click here to add authors to this submission.</li><li>2. <b>Abstract Information</b> Click here to complete the Abstract Information</li><li>3. <b>Additional Question - Requesting Poster Only (not required)</b> Poster-Only Acceptance Option</li><li>4. <b>Attestation &amp; Electronic Signature</b> Click here to complete the attestation task.</li></ol> <p>Save Submission</p>	<p><b>XXI Test Abstract ENCORE</b> Abstract ID: 2082255 Abstract Type: Encore Category: Clinical-based research Abstract Status: Active</p> <p>New abstract was successfully added.</p> <ol style="list-style-type: none"><li>1. <b>Author Information</b> Click here to add authors to this submission.</li><li>2. <b>Abstract Information</b> Click here to complete the Abstract Information</li><li>3. <b>Additional Questions - Encore Details</b> Click here to complete the Additional Questions Task.</li><li>4. <b>Additional Question - Requesting Poster Only (not required)</b> Poster-Only Acceptance Option</li><li>5. <b>Attestation &amp; Electronic Signature</b> Click here to complete the attestation task.</li></ol> <p>Save Submission</p>	<p><b>XXI Test Abstract TRIALS IN PROGRESS</b> Abstract ID: 2082259 Abstract Type: Trials In Progress Category: Real-world evidence Abstract Status: Active</p> <p>New abstract was successfully added.</p> <ol style="list-style-type: none"><li>1. <b>Author Information</b> Click here to add authors to this submission.</li><li>2. <b>Abstract Information</b> Click here to complete the Abstract Information</li><li>3. <b>Additional Questions - Trials in Progress Details</b> Click here to complete the Additional Questions Task.</li><li>4. <b>Additional Question - Requesting Poster Only (not required)</b> Poster-Only Acceptance Option</li><li>5. <b>Attestation &amp; Electronic Signature</b> Click here to complete the attestation task.</li></ol> <p>Save Submission</p>

## AUTHOR INFORMATION

- Add at least 1 author and no more than 50
- Maximum of 1 primary author
- The submitting author will default as the Primary Author but can be changed within the Author Profile area under Author Role

Please ensure the Author Profile Professional Information area is filled out completely and correctly. This will be the area that will provide author affiliation listings for conference materials as well as the publication.

As you add additional authors, please be consistent when listing departments and affiliations.

**Professional Information** (as it will appear on conference materials)

**Position** (max character 100)

  
**Department**

**Affiliation (NAME ONLY) \***

**Degree / Credentials \***

While the Primary Author must provide complete contact information in the abstract submission system, a profile image and biographical sketch are optional.

The primary author will receive all correspondence from iwCLL regarding the status of the abstract and instructions regarding presentation and publishing.

## ABSTRACT INFORMATION

### ABSTRACT TITLE

- 300-character limit, including spaces
- Not counted toward total word count

The screenshot shows a web form titled "New Abstract" with a breadcrumb "Home / New Abstract". A green plus icon is next to the heading "START A NEW ABSTRACT" and a blue "Submit" button is in the top right. The form has three main sections: "Abstract Title" with a text input field and character/word counts; "Abstract Type" with a dropdown menu; and "Category" with another dropdown menu. A final "Submit" button is at the bottom. Three orange callout boxes are connected to the form: one to the title field, one to the abstract type dropdown, and one to the category dropdown.

#### Abstract Title \*

An Abstract must have a short, specific presentation title (containing no abbreviations) that indicates the nature of the presentation.

0 characters (300 max)  
0 words (75 max)

#### Abstract Type \*

[View Abstract Type descriptions.](#)

#### Category \*

[View Category descriptions.](#)

Submit

### ABSTRACT TYPE

- General
- Encore
- Trials in Progress (TiP)
- Late-Breaking General

### CATEGORY

- Laboratory-based research
- Clinical-based research
- Real-world evidence

## ABSTRACT INFORMATION

### TOPIC: PATHOGENESIS OF CLL

- Novel Insights Into the Pathogenesis of CLL
- Genomics, Epigenetics, and Proteomics of CLL
- Immunology and the Tumor Microenvironment
- Preclinical Studies of Novel Therapies

### TOPIC: THERAPY OF CLL

- Frontline CLL Therapy
- Relapsed, Double Relapsed, and/or Refractory CLL
- Richter Transformation
- Health Maintenance for Patients With CLL
- Novel Therapies for CLL I: Non-Immunological Approaches
- Novel Therapies for CLL II: Immunological Approaches
- Patient Experience and CLL in Resource Limited Countries

**Abstract Title \***  
An Abstract must have a short, specific presentation title (containing no abbreviations) that indicates the nature of the presentation.

Test Abstract 13 characters (Max 300 characters)  
12 words (Max 70 words)

**Topic \***  
Please select one of the below main topics that your abstract is related to. Topics will be used to best place selected abstracts within the program agenda.

Pathogenesis of CLL

**Identify of which meeting submission is intended for \***

Young Investigator Meeting (YIM)

**Are you submitting from an Official Development Assistance (ODA)-eligible country? \***

No

**Abstract Text \***  
Please paste your abstract text below.

- 700-word limit (includes headers)
- PACT I/II/III: All author information
- Structure is permitted, but not required
- References are to be cited within the text; no footnotes
- Must be in English

THE ABSTRACT TEXT WILL APPEAR EXACTLY AS IT IS SUBMITTED IN ALL PROGRAM MATERIALS. ADDITIONALLY, ABSTRACTS WILL BE TYPESET BY LEUKEMIA & LYMPHOMA IN THE TEXT PROVIDED WITHOUT COPYEDITING CHANGES.

Abstract Text here. No Author Information. In-text citations; no footnotes!

75 characters  
10 words (Max 700 words)

**Keywords \***  
(leukemia, relapsed/refractory, biomarker, etc). Please limit the keywords to 3.

Put keywords here

17 characters  
3 words

### ADDITIONAL QUESTIONS

Identify which meeting the submission is intended for:

- Young Investigator Meeting (YIM)
- iwCLL Main Meeting
- Both YIM & iwCLL Main Meeting

Are you submitting from an Official Development Assistance (ODA)-eligible country?

- Yes
- No

Those submitting from an ODA-eligible country will receive a separate committee review. Additionally, the top 2 scoring ODA-eligible abstracts will receive travel awards.

### SUBMITTED KEYWORDS

Limit to 3 (leukemia, relapsed/refractory, biomarker, etc.)

### ABSTRACT TEXT

- 700-word limit (includes headers)
- EXCLUDE all author information
- Structure is permitted, but not required
- References are to be cited within the text, no footnotes
- Must be in English


Abstracts will be typeset by the journal in the text provided without copyediting changes. The abstract text will appear exactly as it is submitted.




## ADDITIONAL QUESTIONS – Poster-Only Considerations (not required)

During submission, you may elect to have your abstract considered for a “Poster-Only” acceptance through a non-required task.

By making this selection, your abstract will not be considered for any other award category but Poster-Only, regardless of the score. This selection may be helpful for authors who may not be able to give a presentation in English or are unable to travel to Poland.



 EDIT ADDITIONAL QUESTION - REQUESTING POSTER ONLY (... Continue)

*ONLY COMPLETE THIS TASK IF YOU WANT YOUR ABSTRACT TO BE CONSIDERED FOR A POSTER-ONLY ACCEPTANCE.*

By making this selection, your abstract will not be considered for any other award category but POSTER-ONLY, regardless of the score.

This selection may be helpful for authors who may not be able to give a presentation in English or are unable to travel to Poland.

This election cannot be changed after the Review Committee has reached its decision. \* indicates a required field

**1** Poster Only Acceptance

Please consider my abstract for POSTER-ONLY Acceptance

Continue

This election must be made during the submission process and cannot be changed after the review committee has reached its decision.

## ADDITIONAL QUESTIONS – ENCORE and TiP Abstract Types (Required)

### ENCORE

**1** I declare that some of the content of the abstract has already been presented at another event prior to iwCLL 2025. \*  
Encores will not be accepted if published/presented prior to April 6, 2025.

**2** Please specify exactly what data have changed since original publication \*

**3** Was the encore selected as an oral, poster, or published only? \*  
Select One

**4** Please specify the name and date of the meeting where the project was presented.  
If you do not wish to answer, please type N/A

- Declaration of Encore
- Data changes since original publication
- Selected as an oral, a poster, or published only
- Name and date of meeting where project was presented

### TiP

**1** Is this clinical trial registered? \*  
Select One.

**2** Select the registry below.  
Select One.

**3** Registry (other)  
If you selected 'Other' above, please type your Registry here.

**4** Registration Number

**5** Please indicate whether patients are still being accrued to the trial reported in this abstract:

- Registered status
- Registry type
- Registration #
- Patient accrual (Yes, No, Enrollment has not started)

## ATTESTATION & ELECTRONIC SIGNATURE

**You will be asked to read and agree through electronic signature to the terms below.**

This certifies the submitting author's understanding of and agreement to the abstract submission guidelines and rules.

**Agreement for Presentation:** I agree to present the abstract if it is selected for the presentation at the meeting. This includes registering for the meeting and being physically present during the scheduled time of the session.

**Abstract Text Confirmation:** I agree that I have proofread my abstract text to ensure that it does not require any updates and acknowledge and agree that it will be reproduced exactly as submitted both online (on the conference website) and in the publication.

**Publishing Attestation:** I understand that this abstract cannot be withdrawn after **01 August 2025** and will appear in the meeting publications.


**Abstract Policy Compliance:** I agree that the author shall be the owner of all copyrights related to the content contained in both the printed and electronic Poster and/or submission. Author hereby grants to iwCLL an irrevocable, perpetual license to maintain, store, cache, copy and distribute (in any current or future media) the Poster and/or submission (the "License Grant"). The License Grant includes iwCLL's right to include the Poster and/or submission in its current and future database or databases as well as to distribute the Poster electronically to third parties through any one or more websites operated by or on behalf of iwCLL. Author hereby represents and warrants to iwCLL that: (i) Author is the owner or authorized licensee of all right, title and interest (including all copyrights and other intellectual property rights) in and to all content that appears on the Poster and/or submission; (ii) all content that appears in the Poster and/or submission is the Author's original work and contains no libelous or unlawful statements, does not infringe on the rights or privacy of others or contain material or instructions that might cause harm or injury, (iii) Author's License Grant does not and shall not constitute a breach of, or otherwise violate, any written or verbal understanding or agreement between Author and any third party; and (iv) iwCLL's use of the files provided by the Author to create the Poster and/or submission, as well as iwCLL's exercise of its rights pursuant to the License Grant, shall not infringe or violate the copyrights, or other intellectual property rights, of any third party.




## SUBMISSION

Upon completion of all Abstract Tasks, you will see green circle check marks next to each Task indicating it has been completed.

Click the BLUE Save Submission button on the top right screen of the TASK LIST page to confirm all of the tasks have been completed.



Home / Abstract / Task List for 'XXI Test Abstract'

 **TASK LIST** [Save Submission](#)


Please click on each task below to enter the requested information.

Once completed, the task will then appear with a large **green check mark**.


After you have completed all of the tasks below, select "Save Submission".

[XXI Test Abstract](#)  
Abstract ID: 2082242  
Abstract Type: General Abstract  
Category: Laboratory-based research  
Abstract Status: Active

You will be brought to the **ABSTRACT SUMMARY** page where you must click the **BLUE Submit** button on the top right screen to formally submit your abstract.







Home / Abstract / Tasks / Submit

 **ABSTRACT SUMMARY** [Submit](#)

[XXI Test Abstract](#)  
Abstract ID: 2082242  
Abstract Type: General Abstract  
Category: Laboratory based research  
Abstract Status: Active

Thank you! Your tasks for this submission are complete. Please use the blue [Submit](#) button at the top to formally submit your abstract. You may also click the link at the bottom of the task list for a preview of your abstract.

-  **1. Author Information**  
Completed - Monday, 10 March, 2025, 3:53 PM
-  **2. Abstract Information**  
Completed - Monday, 10 March, 2025, 3:54 PM
-  **3. Additional Question - Requesting Poster Only (not required)**  
Completed - Monday, 10 March, 2025, 3:54 PM
-  **4. Attestation & Electronic Signature**  
Completed - Monday, 10 March, 2025, 3:54 PM

## REVISIONS

No revisions to the abstract submission (authors and content) can be made after the abstract submission deadline of **30 May 2025**. It is the responsibility of the submitting author to ensure that the submission does not contain any errors as it will be reproduced exactly as submitted on the conference website as well as in the published in a peer-reviewed journal supplement.

## PUBLICATIONS

Accepted abstracts of all categories (Oral, Oral Poster, YIM Oral, YIM Oral Poster, and Poster) are published in a special supplement of a peer-reviewed journal. Unless an author initiates a withdrawal before the withdrawal deadline of **01 August 2025**, all abstracts accepted for inclusion in the XXI iwCLL conference agree that their abstracts will be included in the published supplement.


**Abstracts will be typeset from the text submitted by the author without copyediting changes, and no figures or tables will be included. It is the responsibility of the submitting author to ensure that all author affiliation information and abstract text is exactly as they want it to appear in a publication.**



# WITHDRAWAL


Submitted abstracts may be withdrawn through **01 August 2025**.

The process for withdrawing a submitted abstract is as follows:



The screenshot shows the main portal page with a dark blue header containing 'Home | Log Out' and 'Conference Details | Technical Support'. The main content area is divided into three columns: 'EVENT INFORMATION' (iwCLL 2025, 12-15 September 2025, Krakow), 'YOUR PROFILE' (Allison Heintz, Bio Ascend LLC), and 'SUBMIT FEEDBACK'. Below these is an 'ABSTRACT' section with a '+ Click here to begin a new abstract' link and a 'Test Abstract' entry with a green checkmark and status 'Complete (Submitted 13/03/2025, 10:59 AM)'. A red line connects the 'Test Abstract' link to a callout box on the right.

Click on the submission from the main portal page



The screenshot shows the 'TASK LIST' page for the 'Test Abstract'. The header includes 'Home / Abstract / Task List for "Test Abstract"'. A 'Save Submission' button is in the top right. A light blue box contains instructions: 'Please click on each task below to enter the requested information. Once completed, the task will then appear with a large green check mark. After you have completed all of the tasks below, select "Save Submission".' Below this is a task card for 'Test Abstract' with details: 'Abstract ID: 2082173', 'Abstract Type: General Abstract', 'Category: Laboratory-based research', and 'Abstract Status: Complete'. A red line connects the 'Test Abstract' title to a callout box on the right.

Click the Submission Title

Update the Abstract Status drop down from “Complete” to “Withdrawn”

Home / Edit Abstract: Test Abstract

### EDIT ABSTRACT: TEST ABSTRACT

[Update Abstract](#)

Editing your Abstract's settings is easy. Just adjust the fields below and press the 'Update Abstract' button.

**Abstract Title \***  
An Abstract must have a short, specific presentation title (containing no abbreviations) that indicates the nature of the presentation.

Test Abstract 13 characters (300 max)  
2 words (75 max)

**Abstract Type \***  
General Abstract

**Abstract Type Descriptions**

**General Abstract**  
All types of clinical based and laboratory based research projects relating to CLL, SLL, and related B cell lymphoproliferative disorders are eligible for submission.

**Encore**  
Abstracts containing updated data with respect to a previous presentation may be submitted. Authors must supply information regarding the original presentation for identification and comparison purposes, indicating the name of the meeting, year and/or publication number. Abstracts will NOT be accepted if published or presented prior to 06 April 2025.

**Trials In Progress**  
Indicate if the trial has been registered, the registry, and the registration number.

**Category \***  
Laboratory-based research

**Abstract Status \***  
Withdrawn  
-- Select Abstract Status --  
Active  
Withdrawn  
Complete

Click “Update Abstract” button on the top left to complete the withdrawal process.

Abstracts may not be withdrawn after 01 August 2025. Otherwise, the abstract will be published both on the conference website as well as the published in a peer-reviewed journal supplement.

# COMMON FAQs

---

## **Does the presenting author need to be the primary author?**

No, the presenting author does **not** need to be the lead author but must be an abstract co-author. Non-authors are **not** allowed to present.

## **Does the presenting author have to attend the meeting in person?**

Yes, presenting authors must attend the XXI iwCLL meeting in person in Krakow, Poland.

## **Can industry-affiliated authors present?**

No. Industry authors can submit abstracts but CANNOT present. Please note: content must be free of any form of advertising and any form of bias (eg, using a commercial supporter's name or display of brand name, or use of sponsor logos). Abstracts must be scientifically relevant and/or are trials in progress.

## **Are Encore abstracts required to contain updated information or can they be a direct Encore of a previous meeting?**

While the intent/preference of the Encore is to present abstracts that have been previously presented with updated data, we will not make it a requirement, in that it will not be an element that will necessarily exclude it from consideration.

## **Is there a preferred format (eg, AMA style) or examples for the in-text citations?**

There is no preferred format for in-text citations. Please do not utilize footnotes.

## **Does the field “Please indicate how this research was funded” apply to direct funding for the project or funding/conflicts of interest from the authors?**

When indicating how the research was funded, please outline the funding source of the abstract (NIH, a pharmaceutical company, a foundation, other sources, etc) Upon acceptance of an Oral or Oral Poster abstract, presenting authors will be required to provide COI/disclosure information at that time.

## **If I am not selected to present at the meeting, can I withdraw my abstract from being published in the journal supplement?**

All accepted abstracts, whether for presentation or poster, will be published in the journal supplement. If an author does not want their abstract published, they must fully withdraw the entire abstract from the conference via the abstract system by the 01 August 2025 deadline.



**Any questions regarding abstract submissions should be sent to [abstracts\\_iwcll@bioascend.com](mailto:abstracts_iwcll@bioascend.com).**